NeuroproteXeon is seeking international distribution partners to help us achieve our mission. We have completed the preclinical studies necessary for the filing of an IND (US) and RMS & CMS (EU). We own exclusive worldwide, royalty-free rights to Xenon + Xenex™ therapy.

Xenex™ is an inhaled gas that has shown promising potential as a neuroprotectant when administrated to a patient after a cardiac arrest, in combination with hypothermia/targeted temperature management [TH/TTM] therapy.

Phase II Superiority Study, published in JAMA in March 2016, showed statistically significantly less brain damage and directionally positive survival outcomes between a xenon plus TTM group versus a TTM alone group.  Overall the study showed:

  • Less brain damage
  • Improved survival outcome
  • Non toxicity

Contact: All partnering inquiries should be directed to